Advertisement BioTime Q2 revenues rise - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

BioTime Q2 revenues rise

BioTime, a developer of regenerative medicine, reported total revenues of $755,553 for the second quarter ended 30 June 2011, an increase of 11%, compared to $680,278 for the same period in 2010.

The company has posted a net loss of $5m for the second quarter of 2011, compared to $2.35m for the same period in 2010.

The company’s loss from operations were $4.98m, compared to 2.32m for the same period prior year.

For the six months ended 30 June 2011, the company reported total revenues of $1.58m, compared to $1.45m for the same period in 2010.

BioTime has reported net loss of $8.94m for the six months ended 30 June 2011, compared to $3.67m for the same period in 2010.

For the six months ended 30 June 2011, the company’s loss form operations were $9.01m, compared to $3.64m for the same period prior year.